GSK plc 6-K, filed May 7, 2025
GSK plc (GSK)
6-K
2025-05-07
For: 2025-05-07
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on May 7, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of May 2025
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
79 New Oxford Street, London, WC1A 1DG
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
GSK plc
Results of 25th Annual
General Meeting
GSK
plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm
on Wednesday 7 May 2025 at The Landmark London, 222 Marylebone
Road, London, NW1 6JQ. Shareholders were able to join the meeting
in person or virtually via the Lumi AGM website and
Zoom.
All
valid proxy votes (whether submitted electronically or in hard copy
form) were included in the poll taken at the meeting.
All 25 resolutions were passed
and decided upon by a poll. The table below shows the results for
each resolution. The full text of the resolutions is contained in
the Notice of AGM published on 24 March 2025, which is available on
GSK's website at www.gsk.com.
|
Resolution
|
Total votes for(1)(2)
|
%
|
Total votes against(2)
|
%
|
Total votes cast
|
% of Issued Share Capital voted(3)
|
Votes withheld(4)
|
|
|
1
|
Receive
and adopt the 2024 Annual Report
|
3,031,647,740
|
99.82
|
5,472,209
|
0.18
|
3,037,119,949
|
73.91%
|
12,204,390
|
|
2
|
Approve
the Annual report on remuneration
|
2,810,183,626
|
92.46
|
229,176,108
|
7.54
|
3,039,359,734
|
73.97%
|
9,979,421
|
|
3
|
Approve
the Remuneration policy
|
2,786,567,742
|
93.10
|
206,384,696
|
6.90
|
2,992,952,438
|
72.84%
|
56,376,703
|
|
4
|
Election
of Dr Gavin Screaton
|
3,040,206,238
|
99.89
|
3,385,136
|
0.11
|
3,043,591,374
|
74.07%
|
5,719,426
|
|
5
|
Re-election
of Sir Jonathan Symonds
|
2,947,917,394
|
98.40
|
48,075,530
|
1.60
|
2,995,992,924
|
72.91%
|
53,319,043
|
|
6
|
Re-election
of Dame Emma Walmsley
|
3,038,248,728
|
99.82
|
5,613,533
|
0.18
|
3,043,862,261
|
74.08%
|
5,444,311
|
|
7
|
Re-election
of Julie Brown
|
3,034,344,765
|
99.69
|
9,515,889
|
0.31
|
3,043,860,654
|
74.08%
|
5,460,463
|
|
8
|
Re-election
of Elizabeth McKee Anderson
|
2,941,679,748
|
96.64
|
102,161,424
|
3.36
|
3,043,841,172
|
74.08%
|
5,465,676
|
|
9
|
Re-election
of Charles Bancroft
|
2,956,308,387
|
97.13
|
87,450,752
|
2.87
|
3,043,759,139
|
74.07%
|
5,553,709
|
|
10
|
Re-election
of Dr Hal Barron
|
3,039,339,475
|
99.85
|
4,466,176
|
0.15
|
3,043,805,651
|
74.08%
|
5,489,801
|
|
11
|
Re-election
of Dr Anne Beal
|
2,955,431,838
|
97.09
|
88,492,673
|
2.91
|
3,043,924,511
|
74.08%
|
5,388,566
|
|
12
|
Re-election
of Wendy Becker
|
2,933,164,994
|
96.36
|
110,745,350
|
3.64
|
3,043,910,344
|
74.08%
|
5,400,009
|
|
13
|
Re-election
of Dr Harry C Dietz
|
3,039,383,688
|
99.86
|
4,369,000
|
0.14
|
3,043,752,688
|
74.07%
|
5,560,851
|
|
14
|
Re-election
of Dr Jeannie Lee
|
3,039,577,387
|
99.86
|
4,161,377
|
0.14
|
3,043,738,764
|
74.07%
|
5,574,652
|
|
15
|
Re-election
of Dr Vishal Sikka
|
3,038,858,707
|
99.84
|
4,756,490
|
0.16
|
3,043,615,197
|
74.07%
|
5,688,803
|
|
16
|
Re-appointment
of the auditor
|
3,025,673,462
|
99.89
|
3,223,574
|
0.11
|
3,028,897,036
|
73.71%
|
20,430,064
|
|
17
|
Remuneration
of the auditor
|
3,039,931,435
|
99.88
|
3,782,302
|
0.12
|
3,043,713,737
|
74.07%
|
5,591,584
|
|
18
|
Authority
for the company to make donations to political organisations and
incur political expenditure
|
2,946,755,927
|
99.01
|
29,581,561
|
0.99
|
2,976,337,488
|
72.43%
|
72,977,673
|
|
19
|
Authority
to allot shares
|
2,899,903,495
|
95.30
|
143,133,156
|
4.70
|
3,043,036,651
|
74.06%
|
6,282,441
|
|
20
|
Disapplication
of pre-emption rights - general power(5)
|
2,941,521,597
|
96.72
|
99,811,731
|
3.28
|
3,041,333,328
|
74.02%
|
7,942,085
|
|
21
|
Disapplication
of pre-emption rights - in connection with an acquisition or
specified capital investment(5)
|
2,962,038,875
|
97.39
|
79,351,038
|
2.61
|
3,041,389,913
|
74.02%
|
7,904,048
|
|
22
|
Authority
for the company to purchase its own shares(5)
|
3,036,538,826
|
99.83
|
5,280,936
|
0.17
|
3,041,819,762
|
74.03%
|
7,499,989
|
|
23
|
Exemption
from statement of senior statutory auditor's name
|
3,022,840,749
|
99.74
|
7,951,051
|
0.26
|
3,030,791,800
|
73.76%
|
18,502,136
|
|
24
|
Authority
for reduced notice of a general meeting other than an
AGM(5)
|
2,863,892,275
|
94.11
|
179,242,127
|
5.89
|
3,043,134,402
|
74.06%
|
6,172,307
|
|
25
|
Approve
the adoption of the GSK Share Value Plan
|
2,972,805,515
|
99.56
|
13,033,137
|
0.44
|
2,985,838,652
|
72.67%
|
63,503,752
|
Notes:
(1)
The "for" votes include those giving the Chair
discretion.
(2)
Votes "for" and "against" are expressed as a percentage of the
total votes cast.
(3) The Company's issued share
capital as at 2 May 2025 consisted of 4,109,037,095 shares of 31
¼ pence each ('Ordinary Shares') excluding Ordinary Shares
held in Treasury. Every shareholder has
one vote for every Ordinary Share held.
(4)
A "vote withheld" is not a vote in law and is not
counted in the calculation of the proportion of votes "for" or
"against" a resolution.
(5)
Indicates Special Resolutions requiring a 75% majority of votes
cast.
The following table provides further information on participation
in the AGM:
|
|
GSK's 25th AGM
(Hybrid meeting)
(2025)
|
GSK's
24th AGM
(Hybrid
meeting)
(2024)
|
|
Issued share capital (excluding Treasury Shares)
|
4,109,037,095
|
4,314,108,510
|
|
Total votes cast and votes withheld lodged as a % of GSK's issued
share capital (excluding Treasury Shares)
|
74.21%
|
73.11%
|
|
Total shareholder population
|
86,241
|
60,448
|
|
Total number of proxies lodged
|
3,743
|
2,886
|
|
Number of shareholders in attendance
|
130 in
person
25
participated virtually
|
125 in
person
38
participated virtually
|
|
% of shareholders who lodged proxies
|
4.34%
|
4.77%
|
The above poll results will
shortly be available on the company's website at www.gsk.com.
In accordance with Listing Rule
6.4.2 of the Financial Conduct Authority's (FCA) Listing Rules, a
copy of the resolutions, other than those concerning ordinary
business, will be submitted to the FCA and will, in due course, be
available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
V A Whyte
Company Secretary
7 May 2025
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: May
07, 2025
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|